JP2021502829A5 - - Google Patents

Download PDF

Info

Publication number
JP2021502829A5
JP2021502829A5 JP2020544387A JP2020544387A JP2021502829A5 JP 2021502829 A5 JP2021502829 A5 JP 2021502829A5 JP 2020544387 A JP2020544387 A JP 2020544387A JP 2020544387 A JP2020544387 A JP 2020544387A JP 2021502829 A5 JP2021502829 A5 JP 2021502829A5
Authority
JP
Japan
Prior art keywords
promoter
antigen
item
cells
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/061003 external-priority patent/WO2019099483A1/en
Publication of JP2021502829A publication Critical patent/JP2021502829A/ja
Publication of JP2021502829A5 publication Critical patent/JP2021502829A5/ja
Pending legal-status Critical Current

Links

JP2020544387A 2017-11-14 2018-11-14 Il−36を分泌する免疫応答性細胞およびその使用 Pending JP2021502829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762585879P 2017-11-14 2017-11-14
US62/585,879 2017-11-14
PCT/US2018/061003 WO2019099483A1 (en) 2017-11-14 2018-11-14 Il-36 secreting immunoresponsive cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2021502829A JP2021502829A (ja) 2021-02-04
JP2021502829A5 true JP2021502829A5 (cg-RX-API-DMAC7.html) 2021-12-23

Family

ID=66538783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544387A Pending JP2021502829A (ja) 2017-11-14 2018-11-14 Il−36を分泌する免疫応答性細胞およびその使用

Country Status (7)

Country Link
US (2) US11766474B2 (cg-RX-API-DMAC7.html)
EP (1) EP3710020A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021502829A (cg-RX-API-DMAC7.html)
CN (1) CN111655270A (cg-RX-API-DMAC7.html)
AU (2) AU2018367452B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082570A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019099483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020327671A1 (en) * 2019-08-13 2022-03-03 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
WO2021055731A1 (en) * 2019-09-20 2021-03-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Il-36 cytokine expressing oncolytic viruses for treating cancer
KR20210058038A (ko) 2019-11-13 2021-05-24 (주)아모레퍼시픽 인터루킨-36 감마를 포함하는 피부 미백용 조성물
CN115701999A (zh) * 2020-07-09 2023-02-14 南京传奇生物科技有限公司 用白介素-36工程化γδT细胞用于免疫疗法
CN112358539A (zh) * 2020-11-16 2021-02-12 桂林医学院附属医院 一种小鼠截短IL-36γ蛋白及其制备方法
KR20240049813A (ko) * 2021-08-24 2024-04-17 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 향상된 암 면역치료법을 위한 il-10 발현 세포
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
EP4448578A1 (en) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies, multispecific antibodies and methods of use
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP2903637B1 (en) * 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3811954A1 (en) * 2013-02-26 2021-04-28 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
US9629877B2 (en) * 2013-05-14 2017-04-25 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (CAR) T-cells
ES2876263T3 (es) * 2014-04-07 2021-11-12 Novartis Ag Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
NZ739448A (en) * 2014-04-10 2019-10-25 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Transgene genetic tags and methods of use
SI3227339T1 (sl) * 2014-12-05 2022-02-28 Memorial Sloan-Kettering Cancer Center Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
WO2016090320A1 (en) * 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CA3002674A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
PT3458474T (pt) * 2016-05-18 2022-11-08 Modernatx Inc Combinações de arnm que codificam polipéptidos de modulação imunitária e as suas utilizações

Similar Documents

Publication Publication Date Title
JP2021502829A5 (cg-RX-API-DMAC7.html)
JP7755890B2 (ja) Car発現ベクター及びcar発現t細胞
US20240059754A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
IL314563A (en) Non-HLA-restricted T-cell receptors and their uses
JP2016508728A5 (cg-RX-API-DMAC7.html)
RU2015140811A (ru) Композиции и способы иммунотерапии
JPWO2019157454A5 (cg-RX-API-DMAC7.html)
Godfrey et al. The role of natural killer cells in immunity against multiple myeloma
JP2021502828A5 (cg-RX-API-DMAC7.html)
JP2017523784A5 (cg-RX-API-DMAC7.html)
JPWO2020088631A5 (cg-RX-API-DMAC7.html)
CA2425862A1 (en) Cd19-specific redirected immune cells
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
EP3394105B1 (en) Chimeric antigen receptor with cytokine receptor activating or blocking domain
US20230398216A1 (en) Chimeric activation receptors
Heiblig et al. Adoptive immunotherapy for acute leukemia: new insights in chimeric antigen receptors
Bisht et al. Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Roeven et al. Immunotherapeutic approaches to treat multiple myeloma
WO2023235440A2 (en) Compositions and methods comprising chimeric adaptor polypeptides
Chekmasova et al. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer
Liegel et al. Cellular immunotherapy as a therapeutic approach in multiple myeloma
JPWO2022098925A5 (cg-RX-API-DMAC7.html)
Riedle et al. In vivo activation and expansion of T cells by a bi‐specific antibody abolishes metastasis formation of human melanoma cells in SCID mice
Zöller Unexpected induction of unresponsiveness by vaccination with transformed Salmonella typhimurium
KR20250089551A (ko) 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법